---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-198578"
form_type: "8-K"
ticker: "APLS"
cik: "0001492422"
company_name: "Apellis Pharmaceuticals, Inc."
filed_at: "2023-07-31T23:59:59+00:00"
generated_at: "2026-06-12T21:57:12.165472+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Apellis Q2 revenue $95.0M; SYFOVRE sales $67.3M; net loss $122.0M

## Summary
- Total US net product revenue of $89.6M: SYFOVRE $67.3M (GA), EMPAVELI $22.3M (PNH).
- Net loss of $122.0M improved from $156.0M loss in Q2 2022; cash $616.3M.
- SYFOVRE reduced nonsubfoveal GA lesion growth up to 45% at Months 24-30 in GALE extension.
- Investigation of rare retinal vasculitis events found no drug product or manufacturing issues.
- R&D expenses $95.7M, G&A $111.4M; company funded into Q1 2025.

## SEC filing metadata
- accession: 0001193125-23-198578
- form_type: 8-K
- ticker: APLS
- cik: 0001492422
- company_name: Apellis Pharmaceuticals, Inc.
- filed_at: 2023-07-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1492422/000119312523198578/0001193125-23-198578-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1492422/000119312523198578/d532845d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-198578
- JSON: https://secwatch.observer/filing/0001193125-23-198578.json
- Plain text: https://secwatch.observer/filing/0001193125-23-198578.txt

## Key facts
- Earnings Releases
  Apellis Pharmaceuticals, Inc. reported the second quarter 2023 results: revenue $95.0 million.
  - Period: the second quarter 2023
  - Revenue: $95.0 million
  - Result: reported results
  source text: total revenue was $95.0 million for the second quarter of 2023, which consisted of $22.3 million of U.S. net product revenue of EMPAVELI, $67.3 million of U.S. net product revenue of SYFOVRE, and additional licensing and other revenue under the Sobi collaboration.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1492422/000119312523198578/0001193125-23-198578-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.